Blood glucose lowering compound

Patent metadata

Field	Value
Publication number	US-10035839-B2
Application number	US-201715434477-A
Country	US
Kind code	B2
Filing date	Feb 16, 2017
Priority date	Feb 24, 2016
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.

First claim

We claim:

1. A compound comprising an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2, and wherein the A and B chains contain a disulfide bond between the cysteine at position 7 of the A chain and the cysteine at position 7 of the B chain, a disulfide bond between the cysteine at position 20 of the A chain and the cysteine at position 19 of the B chain, and a disulfide bond between the cysteine at position 6 of the A chain and the cysteine at position 11 of the A chain.

2. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.

3. A method of treating diabetes in a patient comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

4. A method of treating diabetes in a patient comprising administering to a patient in need thereof an effective amount of the composition of claim 2 .

5. A method of treating hyperglycemia in a patient comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

6. A method of treating hyperglycemia in a patient comprising administering to a patient in need thereof an effective amount of the composition of claim 2 .

Assignees

• Lilly Co Eli
• Amunix Operating Inc

Inventors

• Baldwin David Bruce
• Beals John Michael
• Korytko Andrew Ihor
• McLAUGHLIN Bryant Rhodius
• Schellenberger Volker

Classifications

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title

• C07K14/62

  Insulins · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• A61K38/28

  Insulins · CPC title